Bluejay Diagnostics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Bluejay Diagnostics, Inc. (BJDX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $4.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-12
- Bluejay Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$1.48M.
- Bluejay Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$1.19M, a 361.98% decline year-over-year.
- Bluejay Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $452.65K.
- Bluejay Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$3.33M.
- Bluejay Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $862.93K, a 58.78% decline from fiscal 2024.
- Bluejay Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $2.09M.
- Bluejay Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$7.91M.
- Bluejay Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$8.93M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.43M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | -$1.48M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $862.93K 10-K · filed 2026-03-06 | |||
| 2025-09-30 | -$1.22M 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | $141.13K 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | -$1.19M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $2.09M 10-K · filed 2026-03-06 | |||
| 2024-09-30 | $3.55M 10-Q · filed 2025-11-07 | |||
| 2024-06-30 | $5.85M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $452.65K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$7.91M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$5.04M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$5.01M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$3.33M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$8.93M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | -$5.76M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$3.71M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$1.92M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |